4//SEC Filing
MORTIMER IAN 4
Accession 0000950170-25-009388
CIK 0001582313other
Filed
Jan 26, 7:00 PM ET
Accepted
Jan 27, 8:28 PM ET
Size
23.7 KB
Accession
0000950170-25-009388
Insider Transaction Report
Form 4
MORTIMER IAN
DirectorPRESIDENT & CEO
Transactions
- Exercise/Conversion
Common Shares
2025-01-24$17.76/sh+22,468$399,032→ 53,770 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-01-27−16,315→ 0 totalExercise: $17.76Exp: 2025-03-16→ Common Shares (16,315 underlying) - Exercise/Conversion
Common Shares
2025-01-27$17.76/sh+15,166$269,348→ 46,468 total - Sale
Common Shares
2025-01-27$40.46/sh−15,166$613,616→ 31,302 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-01-24−22,468→ 16,315 totalExercise: $17.76Exp: 2025-03-16→ Common Shares (22,468 underlying) - Exercise/Conversion
Common Shares
2025-01-23$17.76/sh+16,217$288,014→ 47,519 total - Sale
Common Shares
2025-01-23$40.08/sh−16,217$649,977→ 31,302 total - Sale
Common Shares
2025-01-27$41.07/sh−1,149$47,189→ 31,302 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-01-23−16,217→ 38,783 totalExercise: $17.76Exp: 2025-03-16→ Common Shares (16,217 underlying) - Sale
Common Shares
2025-01-24$40.20/sh−22,468$903,214→ 31,302 total - Exercise/Conversion
Common Shares
2025-01-27$17.76/sh+1,149$20,406→ 32,451 total
Holdings
- 14,300(indirect: By Spouse)
Common Shares
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024.
- [F2]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.535, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F5]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $41.01 to $41.145, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F6]The shares subject to the option are fully vested and exercisable.
Documents
Issuer
Xenon Pharmaceuticals Inc.
CIK 0001582313
Entity typeother
Related Parties
1- filerCIK 0001619961
Filing Metadata
- Form type
- 4
- Filed
- Jan 26, 7:00 PM ET
- Accepted
- Jan 27, 8:28 PM ET
- Size
- 23.7 KB